This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Do Options Traders Know Something About Amarin (AMRN) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Amarin (AMRN) stock based on the movements in the options market lately.
What's in the Cards for Amarin (AMRN) This Earnings Season?
by Zacks Equity Research
Amarin's (AMRN) cardiovascular drug, Vascepa to drive sales in the fourth quarter.
Amarin (AMRN) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Amarin (AMRN) closed at $17.35 in the latest trading session, marking a +1.46% move from the prior day.
Amarin (AMRN) Stock Moves -0.49%: What You Should Know
by Zacks Equity Research
Amarin (AMRN) closed at $16.15 in the latest trading session, marking a -0.49% move from the prior day.
Do Options Traders Know Something About Amarin (AMRN) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Amarin (AMRN) stock based on the movements in the options market lately.
Amarin (AMRN) Stock Up on Rumors of Acquisition by Pfizer
by Zacks Equity Research
Amarin (AMRN) shares rally on rumors of its potential; acquisition by large pharmaceutical company, Pfizer. Speculations are rife about rising M&A activity in the pharma space.
Amarin Down on Lower '19 View, Posts Preliminary '18 Results
by Zacks Equity Research
Amarin (AMRN) reports preliminary results for 2018 and issues guidance for 2019. While the results exceeded estimates, outlook missed the same.
Amarin (AMRN) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Amarin (AMRN) closed at $15.02 in the latest trading session, marking a +1.49% move from the prior day.
Are Options Traders Betting on a Big Move in Amarin (AMRN) Stock?
by Zacks Equity Research
Investors need to pay close attention to Amarin (AMRN) stock based on the movements in the options market lately.
Amarin (AMRN) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Amarin (AMRN) closed at $17.67 in the latest trading session, marking a -1.83% move from the prior day.
Amarin's Vascepa Cuts Heart Risk in Outcomes Test, Stock Down
by Zacks Equity Research
Amarin (AMRN) posts detailed data from a late-stage cardiovascular outcomes study on its fish oil drug Vascepa. The stock takes a hit.
Are Options Traders Betting on a Big Move in Amarin (AMRN) Stock?
by Zacks Equity Research
Investors need to pay close attention to Amarin (AMRN) stock based on the movements in the options market lately.
Amarin (AMRN) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Amarin (AMRN) closed the most recent trading day at $22.98, moving +0.48% from the previous trading session.
Amarin (AMRN) Beats Earnings & Misses Revenues in Q3
by Indrajit Bandyopadhyay
Amarin beat earnings estimates while it misses sales in the third quarter of 2018.
What's in the Cards for Amarin (AMRN) This Earnings Season?
by Zacks Equity Research
Amarin (AMRN) is scheduled to release third-quarter earnings on Nov 1.
Amarin (AMRN) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Amarin (AMRN) closed the most recent trading day at $21.96, moving +0.78% from the previous trading session.
Amarin (AMRN) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Amarin (AMRN) closed the most recent trading day at $19.71, moving -1.99% from the previous trading session.
Amarin (AMRN) Stock Moves -1.51%: What You Should Know
by Zacks Equity Research
In the latest trading session, Amarin (AMRN) closed at $17.34, marking a -1.51% move from the previous day.
5 Top Healthcare Mutual Funds to Buy in October
by Zacks Equity Research
Successful drug trials at several biopharmas and FDA approvals make healthcare funds a strong investment option
5 Best Biotech Stocks to Buy In October
by Zacks Equity Research
Successful drug trials at several biopharmas and FDA approvals make biotech companies a strong investment choice in October
Amarin's Stock Soars as Fish Oil Drug Lowers Heart Risks
by Zacks Equity Research
Amarin (AMRN) shares soar on positive results from a cardiovascular outcomes study on Vascepa.
Biotech Stock Roundup: ALXN Soliris Successful, Respite For Sarepta, AMRN Soars
by Zacks Equity Research
Data read-outs by quite a few companies grabbed headlines in the biotech sector this week.
Is the Options Market Predicting a Spike in Amarin (AMRN) Stock?
by Zacks Equity Research
Investors in Amarin (AMRN) need to pay close attention to the stock based on moves in the options market lately.
Is the Options Market Predicting a Spike in Amarin (AMRN) Stock?
by Zacks Equity Research
Investors need to pay close attention to Amarin (AMRN) stock based on the movements in the options market lately.
Are Options Traders Betting on a Big Move in Amarin (AMRN) Stock?
by Zacks Equity Research
Investors need to pay close attention to Amarin (AMRN) stock based on the movements in the options market lately.